Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Equity Ratio (2016 - 2025)

Vistagen Therapeutics' Equity Ratio history spans 12 years, with the latest figure at 0.78 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 10.94% year-over-year to 0.78; the TTM value through Dec 2025 reached 0.78, down 10.94%, while the annual FY2025 figure was 0.83, 9.7% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.78 at Vistagen Therapeutics, down from 0.82 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.94 in Q4 2023 and bottomed at 0.46 in Q2 2023.
  • The 4-year median for Equity Ratio is 0.84 (2023), against an average of 0.83.
  • The largest annual shift saw Equity Ratio soared 285.28% in 2021 before it fell 10.94% in 2025.
  • A 4-year view of Equity Ratio shows it stood at 0.88 in 2021, then increased by 6.48% to 0.94 in 2023, then dropped by 6.57% to 0.88 in 2024, then dropped by 10.94% to 0.78 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Equity Ratio are 0.78 (Q4 2025), 0.82 (Q3 2025), and 0.82 (Q2 2025).